Supporting early phase clinical trials for heart, lung, blood, and sleep disorders in both adults and children, with applicants expected to be ready to start trials within the initial project period.
NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.
Funds Phase I clinical trials for diagnostic/therapeutic interventions in heart, lung, blood, and sleep disorders in adults/children, allowing preclinical activities and milestone-driven support.
NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NIH's R21 grant supports early-stage, high-risk clinical trial research with potential for breakthroughs in biomedical, behavioral, or clinical fields.